Search

Search Constraints

You searched for: Author/Creator Abi-Saab, Danielle

Search Results

1. DT‐01‐02: CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN‐LABEL EXTENSION STUDIES. (1st July 2019)

2. O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY. (1st July 2006)

3. O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES. (1st July 2006)

4. O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION. (1st July 2006)

5. O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION. (1st July 2006)

6. O3‐10‐01: CORRELATION BETWEEN AMYLOID REDUCTION AND CLINICAL OUTCOMES: EXPLORATORY ANALYSES FROM THE GANTENERUMAB SCARLET ROAD AND MARGUERITE ROAD OPEN‐LABEL EXTENSION STUDIES. (1st July 2019)